CJC-1295 and ipamorelin: what the two-pathway research shows

Two keys, two locks — and what the research does and does not show.

TL;DR

• CJC-1295 and ipamorelin act on two different pituitary pathways.
• In a 1990 study in healthy men, GHRH plus an older growth hormone-releasing peptide released more growth hormone than either alone. That study did not test CJC-1295 or ipamorelin.
• Neither is FDA-approved.

What it is

CJC-1295 is a GHRH analog (in plain English: a copy of growth-hormone-releasing hormone, the natural signal from the brain). Ipamorelin is a ghrelin mimetic (in plain English: a copy of the "stomach hunger signal" that also tells the pituitary to release growth hormone). Both act on the pituitary gland's release of growth hormone, but they push on different buttons. In the research literature, pairing these two classes is called GHRH-plus-GHRP.

How it works

Imagine the pituitary gland as a door with two separate locks. CJC-1295 has the GHRH key. Ipamorelin has the ghrelin key. Turning either lock alone opens the door part of the way. In a 1990 study in healthy men, turning both at once — GHRH plus an older GHRP — opened it wider. That study did not test CJC-1295 or ipamorelin. Ipamorelin is also unusual among ghrelin mimetics because it did not raise cortisol in published animal data.

Who asks about it

People come to this topic after hearing CJC-1295 or ipamorelin mentioned on a podcast or online. They want to understand why the two are so often named together.

What the research says

A 1990 study in the Journal of Clinical Endocrinology and Metabolism found that low doses of a GHRP given together with GHRH released more GH in healthy men than the sum of each given alone — a synergistic effect. That study used an older GHRP, not ipamorelin, and did not test CJC-1295. Effects on body composition or recovery have not been established for CJC-1295 and ipamorelin together.

What to know

Compounded CJC-1295 and ipamorelin are not FDA-approved. Side effects in the published literature include injection-site reactions, water retention, and tingling. Long-term safety in healthy adults has not been established.

The Halftime POV

We explain mechanism so readers can tell the research from the marketing. The dual-pathway logic is real and well-cited for older peptides. It has not been shown to make CJC-1295 and ipamorelin together safe or effective for anyone.

Related reading:

• CJC-1295 + ipamorelin combination: an overview
• CJC-1295: mechanism, in plain English
• The growth hormone axis explained

FAQ

Q: Why are CJC-1295 and ipamorelin discussed together? A: They act on two different pituitary pathways. In a 1990 study in healthy men, GHRH given with an older growth hormone-releasing peptide released more growth hormone than either alone. That study did not test CJC-1295 or ipamorelin.

Q: Is the combination FDA-approved? A: No. Compounded versions of CJC-1295 and ipamorelin are not FDA-approved. As of September 14, 2026, neither is in any FDA 503A category and neither is on the 503A bulks list.

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved.

Sources

• Bowers CY, et al. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. Journal of Clinical Endocrinology and Metabolism, 1990. https://pubmed.ncbi.nlm.nih.gov/2108187/
• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998. https://pubmed.ncbi.nlm.nih.gov/9849822/
• US Food and Drug Administration. Pharmacy compounding overview. https://www.fda.gov/drugs/human-drug-compounding

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.